Hyperthermic intraperitoneal perfusion chemotherapy--views on the observed variability in oxaliplatin pharmacokinetics.
Srinivas
Nuggehally R
NR
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D010478:Chemotherapy, Cancer, Regional Perfusion; D006801:Humans; D007263:Infusions, Parenteral; D007274:Injections, Intraperitoneal; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D013054:Spectrophotometry, Atomic; D013696:Temperature
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011725:Pyridines; C431073:oxiplatin